{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:05:21Z","timestamp":1790935521531,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Once-monthly (50\/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year.<\/jats:p>\n               <jats:p>Introduction: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in osteoporosis, evidence from randomized clinical trials in several other chronic conditions shows that reducing dosing frequency enhances therapeutic adherence. Ibandronate is a new and potent bisphosphonate with antifracture efficacy proven for daily administration and also intermittent administration with a dose-free interval of &amp;gt;2 months. This report presents comparative data on the efficacy and safety of monthly and daily oral ibandronate regimens.<\/jats:p>\n               <jats:p>Materials and Methods: MOBILE is a 2-year, randomized, double-blind, phase III, noninferiority trial. A total of 1609 women with postmenopausal osteoporosis were assigned to one of four oral ibandronate regimens: 2.5 mg daily, 50 mg\/50 mg monthly (single doses, consecutive days), 100 mg monthly, or 150 mg monthly.<\/jats:p>\n               <jats:p>Results: After 1 year, lumbar spine BMD increased by 3.9%, 4.3%, 4.1%, and 4.9% in the 2.5, 50 \/50, 100, and 150 mg arms, respectively. All monthly regimens were proven noninferior, and the 150 mg regimen superior, to the daily regimen. All monthly regimens produced similar hip BMD gains, which were larger than those with the daily regimen. All regimens similarly decreased serum levels of C-telopeptide, a biochemical marker of bone resorption. Compared with the daily regimen, a significantly larger proportion of women receiving the 100 and 150 mg monthly regimens achieved predefined threshold levels for percent change from baseline in lumbar spine (6%) or total hip BMD (3%). All regimens were similarly well tolerated.<\/jats:p>\n               <jats:p>Conclusions: Monthly ibandronate is at least as effective and well tolerated as the currently approved daily ibandronate regimen in postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1359\/jbmr.050313","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T09:06:25Z","timestamp":1146128785000},"page":"1315-1322","source":"Crossref","is-referenced-by-count":266,"title":["Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study"],"prefix":"10.1093","volume":"20","author":[{"given":"Paul D","family":"Miller","sequence":"first","affiliation":[{"name":"Colorado Center for Bone Research, Lakewood, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Mcclung","sequence":"additional","affiliation":[{"name":"Oregon Osteoporosis Center, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviu","family":"Macovei","sequence":"additional","affiliation":[{"name":"SANA Medical Center, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A","family":"Stakkestad","sequence":"additional","affiliation":[{"name":"CECOR AS, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Luckey","sequence":"additional","affiliation":[{"name":"Saint Barnabas Ambulatory Care Center, Livingston, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bonvoisin","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R","family":"Recker","sequence":"additional","affiliation":[{"name":"Creighton University, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hughes","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[{"name":"Charit\u00e9-University Medicine Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D","family":"Delmas","sequence":"additional","affiliation":[{"name":"Claude Bernard University and INSERM Research Unit 403, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Kendler","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Bolognese","sequence":"additional","affiliation":[{"name":"Bethesda Health Research, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mairon","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[{"name":"University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019250188700_bib1","volume-title":"Osteoporosis in the European Community: A Call To Action","author":"International Osteoporosis Foundation","year":"2001"},{"key":"2024013019250188700_bib2","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/S0002-9343(97)90023-1","article-title":"The socio-economic burden of fractures: Today and in the 21st century","volume":"103","author":"Johnell","year":"1997","journal-title":"Am J Med"},{"key":"2024013019250188700_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995; report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024013019250188700_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"Perspective. How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013019250188700_bib5","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.1991.00400100100017","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","journal-title":"Arch Intern Med"},{"key":"2024013019250188700_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1532-5415.1995.tb05557.x","article-title":"Late physical and functional effects of osteoporotic fracture in women. The Rancho Bernardo Study","volume":"43","author":"Greendale","year":"1995","journal-title":"J Am Geriatr Soc"},{"key":"2024013019250188700_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","article-title":"Population-based study of survival after osteoporotic fractures","volume":"137","author":"Cooper","year":"1993","journal-title":"Am J Epidemiol"},{"key":"2024013019250188700_bib8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","article-title":"Mortality following fractures in older women. The study of osteoporotic fractures","volume":"156","author":"Browner","year":"1996","journal-title":"Arch Intern Med"},{"key":"2024013019250188700_bib9","author":"Osteoporosis Prevention Diagnosis and Therapy","year":"2000"},{"key":"2024013019250188700_bib10","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019250188700_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019250188700_bib12","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024013019250188700_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2024013019250188700_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019250188700_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","article-title":"Alendronate in the prevention of osteoporosis: 7-year follow-up","volume":"15","author":"Sambrook","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024013019250188700_bib16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2024013019250188700_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"2024013019250188700_bib18","first-page":"S1","article-title":"Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women","volume":"19","author":"Cramer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019250188700_bib19","first-page":"S1","article-title":"Medication persistence is better with weekly bisphosphonates, but it remains suboptimal","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019250188700_bib20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00198-003-1431-2","article-title":"Adherence to bisphosphonate hormone replacement therapy in a tertiary care setting of patients in the CANDOO database","volume":"14","author":"Papaioannou","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024013019250188700_bib21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024013019250188700_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024013019250188700_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019250188700_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"key":"2024013019250188700_bib25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1345\/aph.18198","article-title":"Compliance with sulphonylureas in a health maintenance organization: A pharmacy record-based study","volume":"33","author":"Venturini","year":"1999","journal-title":"Ann Pharmacother"},{"key":"2024013019250188700_bib26","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"8","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"2024013019250188700_bib27","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2337\/diacare.20.10.1512","article-title":"Impact of dosing frequency on patient compliance","volume":"20","author":"Paes","year":"1997","journal-title":"Diabetes Care"},{"key":"2024013019250188700_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024013019250188700_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"issue":"Suppl 7","key":"2024013019250188700_bib30","first-page":"S5","article-title":"Oral monthly ibandronate decreases bone turnover in postmenopausal women with low bone mass: Results from the Monthly Oral Pilot Study (MOPS)","volume":"14","author":"Reginster","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024013019250188700_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019250188700_bib32","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019250188700_bib33","first-page":"1905","article-title":"Statistical principles for clinical trials","volume":"18","author":"ICH Harmonized Tripartite Guideline","year":"1999","journal-title":"Stat Med"},{"key":"2024013019250188700_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"2024013019250188700_bib35","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019250188700_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1 year, randomised, double-blind, placebo controlled dose finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"2024013019250188700_bib37","author":"Merck & Co., Inc.","year":"2004"},{"key":"2024013019250188700_bib38","author":"Procter","year":"2003"},{"key":"2024013019250188700_bib39","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"2024013019250188700_bib40","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.050313","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/8\/1315\/56477384\/5650200801.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/8\/1315\/56477384\/5650200801.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:09:10Z","timestamp":1710342550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/8\/1315-1322\/7593067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.050313","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,8,1]]},"published":{"date-parts":[[2005,8,1]]}}}